Business Wire

SAMSUNG

23.2.2021 11:02:14 CET | Business Wire | Press release

Share
Samsung Introduces 1.4μm 50Mp ISOCELL GN2 with Faster and More True-to-Life Auto-Focusing

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today introduced Samsung ISOCELL GN2, a new 50-megapixel (Mp) image sensor with large 1.4-micrometer (μm)-sized pixels. With enhancements to its predecessor, the ISOCELL GN1, the GN2 offers up to 100Mp imaging, improved auto-focusing through Dual Pixel Pro technology, powerful staggered HDR, and vivid results through Smart ISO Pro, regardless of the lighting environment.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210223005475/en/

“ISOCELL image sensors and its technologies have made vast improvements to deliver the quality and performance one would expect from top-tier prograde cameras,” said Duckhyun Chang, executive vice president of sensor business at Samsung Electronics. “Our new ISOCELL GN2 features Dual Pixel Pro, an innovative all-direction auto-focusing solution that elevates the agility to capture moments as they unfold. Adding on Smart ISO Pro and a variety of advanced pixel technologies, pictures from GN2 are more true-to-life than ever.”

The 1/1.12-inch ISOCELL GN2 is a highly versatile image sensor when it comes to image resolutions. With 50 million 1.4μm-sized pixels on hand, the GN2 offers exceptionally detailed photographs in regular settings. In low-lit environments such as indoors, the sensor can simulate a larger 2.8μm-pixel with four-pixel-binning technology to absorb more light, delivering brighter and sharper images.

For those who appreciate more detail in photographs or are prone to post-processing such as image cropping, the GN2 offers an option to take pictures in 100Mp resolutions. In 100Mp mode, the GN2 meticulously re-arranges the color pixels using an intelligent re-mosaic algorithm, creating three individual layers of 50Mp frames in green, red and blue. These frames are then up-scaled and merged to produce a single ultra-high 100Mp resolution photograph.

The ISOCELL GN2 is Samsung’s first image sensor to offer Dual Pixel Pro, the company’s most advanced phase-detection auto-focus solution yet. By employing two photodiodes within every pixel of the image sensor, Dual Pixel Pro makes use of one hundred million phase detecting agents for ultra-fast auto-focusing. In addition, the solution also offers all-direction focusing by splitting the pixels not only vertically, as with Dual Pixel, but also diagonally. This diagonal cut allows the focusing agents to better recognize the top and bottom of the frame, allowing the sensor to get in focus quickly even when there are no pattern changes in a horizontal direction. Low-light focusing and tracking of moving objects are improved as well, as every pixel of the sensor works as focusing agents.

For taking pictures in mixed-light environments, such as sunsets or indoors with daylight coming through a window, the GN2 increases its dynamic range with a staggered-HDR feature, a time-multiplexed HDR technology that uses rolling shutters over the same pixel arrays to capture multiple frames in short, middle, and long exposures. By maximizing the dynamic range, staggered-HDR ensures rich detail and vivid color in highlights and dark shadows within the scene, making it an ideal solution for shooting high-contrast sights. Staggered-HDR is able to reduce the energy consumption of a sensor by up to 24-percent when compared to the predecessor’s real-time HDR mode, contributing to improved energy efficiency of the overall system.

The GN2 also comes with Smart ISO and Smart ISO Pro. Smart ISO intelligently sets the sensor’s conversion gain, allowing the picture to be taken using an optimal ISO; low ISO for brighter outdoors or high for dimmer indoors. Unlike Smart ISO, which uses readouts from a single ISO per picture, Smart ISO Pro, which uses an intra-scene dual conversion gain (iDCG) solution, takes readouts from both high and low ISO to instantly create high dynamic range images with less motion-artifacts. In addition, in extreme low-light, Smart ISO Pro quickly takes and processes multiple frames in high ISO, raising the light sensitivity close to one-million ISOs and taking mobile night photography to greater heights.

Camera experiences can be more fun and creative with the GN2, where precious moments can be captured more dramatically and everyday events can be turned into short videos. The GN2 supports full-HD videos at 480 frames-per-second (fps) or 4K at 120fps, enabling wider possibilities for mobile video-shooting.

Samsung ISOCELL GN2 is currently in mass production.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, digital appliances, network systems, and memory, system LSI, foundry and LED solutions. For the latest news, please visit the Samsung Newsroom at http://news.samsung.com .

# # #

* Samsung first announced its ISOCELL technology in 2013, which reduces color crosstalk between pixels by placing a physical barrier, allowing small-sized pixels to achieve higher color fidelity. Based on this technology, Samsung introduced the industry’s first 1.0μm-pixel image sensor in 2015 and a 0.9-pixel sensor in 2017. Samsung continues to enhance its pixel isolation methods with ISOCELL Plus and the ISOCELL 2.0 technologies.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye